News
bluebird bio Pauses During 2017 Data Blitz
Clinical-stage gene therapy specialist bluebird bio (NASDAQ: BLUE) reported second-quarter earnings last week, which mostly just served as a reminder of its pipeline progress because revenue and
The 2 Most Important Figures in Valeant's Second-Quarter Report (and Neither Is EPS or Debt)
Earnings season remains in full swing, and tomorrow morning, one of the most popular and embattled drugmakers in the entire market is set to reports its second-quarter results.Valeant Pharmaceuticals
Why Minerva Neurosciences Inc. Fell 31.1% in July
Shares of Minerva Neurosciences (NASDAQ: NERV), a clinical-stage biotech focused on diseases of the central nervous system, fell more than 31% in July, according to data from S&P Global Market
Why Flexion Therapeutics Shares Shot 12.8% Higher in July
After the company hosted an investor's day on July 10, shares in Flexion Therapeutics (NASDAQ: FLXN) jumped 12.8% last month, according to S&P Global Market Intelligence.Flexion Therapeutics doesn't
Here's Why Myokardia Inc. Stock Shot Up Today
Shares of Myokardia Inc. (NASDAQ: MYOK), a clinical-stage biotech developing treatments for inherited heart problems, took flight this morning. Positive data for its lead candidate propelled the stock
Here's Why Impax Laboratories Inc Jumped 18% In July
In response to receiving a double dose of good news from the Food and Drug Administration (FDA) and some bullish commentary from Wall Street, shares of Impax Laboratories (NASDAQ: IPXL), a maker of
Why Horizon Pharma plc Stock Is Rising Today
Horizon Pharma (NASDAQ: HZNP), a specialty pharma company, saw its shares rise by as much as 21% in pre-market trading today. The drugmaker's stock is rising in response to a better-than-expected
These 3 Biotechs Just Crushed Analyst Expectations
Earnings season is under way, and biotech business appears to be booming. But it takes more than just a good quarter to know if a biotech is poised for sustainable, long-term growth. With many
Why You Shouldn't Fear Spark Therapeutics' Upcoming Share Issue
Having your shares in a company heavily diluted by a big secondary share issue is often scary for investors. It's easy to see why; if a company dumps a bucket of new stock on the market, existing
Teva Pharmaceuticals Had a Very Bad Day, in a Very Bad Year
In this Market Foolery podcast segment, host Chris Hill and Motley Fool One's Bill Mann consider how much worse Teva Pharmaceutical Industries (NYSE: TEVA) looks presently, after a second quarter
3 Things You'll Want to Watch in Valeant Pharmaceuticals' Q2 Results
Good news from Valeant Pharmaceuticals (NYSE: VRX)?That's what investors got the last time the drugmaker announced its quarterly results. Valeant posted a profit in the first quarter. Its balance
Dividendeneinnahmen im Juli 2017
Nachfolgend veröffentliche ich die Liste meiner Dividendeneinnahmen nach Steuerabzug im Juli 2017:Wertpapiername Dividende ALTRIA GRP INC. 39,52 € BK NOVA SCOTIA 30,47 € COCA-COLA CO. ....
3 Things You Need to Know About Marijuana Stock Cara Therapeutics
Cara Therapeutics (NASDAQ: CARA) announced its second-quarter financial results after the market closed on Thursday. The next day, Cara stock soared. But it wasn't because of the financial numbers
The Top Stock You Should Consider for Your IRA
If you don't have an individual retirement account (IRA), get one. They provide a great option for accumulating retirement savings on a tax-deferred basis. And with a Roth IRA, you won't have to pay
10 Reasons Cancer Drugs Usually Cost $100,000 or More a Year
If you've picked up a prescription from your local pharmacy recently, you probably don't need me to tell you that prescription drug prices have handily outpaced wage growth and the rate of inflation
Why GW Pharmaceuticals Could Be a Gold Mine for Growth Investors
You've probably heard of the great California gold rush of the mid-19th century. Today, many are flocking to what has been called the "green rush" -- a major wave of money flowing into the marijuana
Tesla Speeds Ahead, While Teva Hits the Skids
On this Market Foolery podcast, host Chris Hill and Motley Fool One's Bill Mann discuss two very different companies with two wildly different places in the market today.As electric-car innovator
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
After boosting its full-year hepatitis C revenue guidance last month, Gilead Sciences' (NASDAQ: GILD) share price has been rallying. However, the Food and Drug Administration approved AbbVie's (NYSE:
Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals: Which Company Reported Better Earnings
Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) are two big-cap biotech stocks, and each recently reported second-quarter financial results that were better than
Here's Why Agenus Inc. Stock Slipped 13.6% in July
Shares of Agenus Inc. (NASDAQ: AGEN), a clinical-stage immuno-oncology company, fell 13.6% in July according to data from S&P Global Market Intelligence. Investors viewed a clinical-trial failure
Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is a staple in the portfolios of conservative long-term investors and seniors alike.For decades, J&J, as the company is more commonly known, has
Celgene vs. Gilead Sciences: Who Reported Better Earnings?
Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD) reported second-quarter earnings that were better than industry-watchers' forecasts, but these two giants' circumstances are very
Quintiles IMS Holdings Continues to Execute
Quintiles IMS Holdings (NYSE: Q), a leading service provider to the healthcare and life sciences industries, reported its second-quarter results on Aug. 3. While year-over-year comparisons continue to
Why Cara Therapeutics Shares Are Surging 23% Today
Cara Therapeutics' (NASDAQ: CARA) stock is surging 23% higher at 3:30 p.m. EDT today after management reported second-quarter financial results yesterday that included an update to its clinical-stage
Exelixis, Inc. Grows Revenue, Eyes Treating More Patients
Sales of Exelixis' (NASDAQ: EXEL) kidney cancer drug Cabometyx continued to grow at a torrid pace in the second quarter, allowing the company to post another profitable quarter.MetricQ2 2017Continue